• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

New Pediatric Labeling Information Database - Detail

  • Print
  • Share
  • E-mail
Pediatric Labeling Date:  11/10/2010
Trade Name:  Vyvanse Capsules
Generic Name or Proper Name (*):  lisdexamfetamine
Indications Studied:  ADHD
Label Changes Summary:  * Expanded indication to include adolescent patients ages13-17 years; previously approved for use in 6-12 years * Most common adverse reactions were decreased appetite, insomnia, and decreased weight* Information on clinical trial, adverse reactions
Product Labeling:  Labeling  Opens a new window
Sponsor:  Shire
Therapeutic Category:  CNS Stimulant